Methods of treatment using CTLA-4 antibodies
View Patent ↗The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
1. A method for inducing or enhancing a memory immune response to an antigen in a human patient, which comprises administering to the patient who has developed a primary immune response to the antigen an anti-CTLA-4 antibody such that plasma concentration of the anti-CTLA-4 antibody is maintained above detectable levels for greater than four months.
2. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered multiple times.
3. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered in an amount and at intervals such that the plasma concentration of anti-CTLA-4 antibody in the patient is at least 2 μg/ml for greater than four months.
4. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered in an amount and at intervals such that the plasma concentration of anti-CTLA-4 antibody in the patient is at least 5 μg/ml for greater than four months.
5. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered in an amount and at intervals such that the plasma concentration of anti-CTLA-4 antibody in the patient is at least 10 μg/ml for greater than four months.
6. The method of claim 1 , wherein the anti-CTLA-4 antibody is a humanized anti-CTLA-4 antibody.
7. The method of claim 1 , wherein the anti-CTLA-4 antibody is a human sequence anti-CTLA-4 antibody.
8. The method of claim 1 , wherein the antigen is a cancer antigen and the patient has been previously treated with surgery to resect a tumor.
9. The method of claim 1 , wherein the antigen is a cancer antigen and the patient has been previously treated with chemotherapy.
10. The method of claim 1 , wherein the antigen is a cancer antigen and the patient has been previously treated with radiation.
11. The method of claim 8 , wherein the cancer antigen is a melanoma antigen.
12. The method of claim 9 , wherein the cancer antigen is a melanoma antigen.
13. The method of claim 10 , wherein the cancer antigen is a melanoma antigen.
14. The method of claim 1 , wherein the patient is immunocompromised.
15. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered in a single dose.
16. The method of claim 1 , wherein administration of the anti-CTLA-4 antibody does not result in detrimental side-effects.
17. A method for inducing or enhancing a memory immune response to an antigen in a human patient, which comprises administering to the patient an anti-CTLA-4 antibody such that plasma concentration of the anti-CTLA-4 antibody is maintained above detectable levels for greater than four months.
18. A method for treating cancer in a human patient by administering to a patient an anti-CTLA-4 antibody such that plasma concentration of the anti-CTLA-4 antibody is maintained above detectable levels for greater than four months.